CDC Website CDC Website

To Join the NPIN community or

Home » Targeting Inflammasomes In Substance Abuse And HIV (R01 Clinical Trial Not Allowed) » Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)

Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)

The scientific objective of this Funding Opportunity Announcement is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

Letter of Intent Date
12/15/19
Application Due Date
1/15/20
Project Start Date
7/1/20
Application Contact
Nadia
Felix
Grants Management Specialist
United States
301-827-5701
felixnl@od.nih.gov
Technical Contact
Shang-Yi Anne
Tsai, PhD
Program Director
stsai@nih.gov
United States
301-827-5842
Fund Duration
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Subjects
Audiences

Fund Number: 

5504

Fund ID: 

RFA-DA-20-026

Last modified: 

9/18/19